Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642000 | 0.84 | CYP2C9 (0.53) | LMNACYP1A2CYP3A4MAOACYP2C9 | |
| SCHEMBL6880667 | 0.82 | CA12 (0.55) | LMNACYP1A2CYP3A4MAOACYP2C9 | |
| SCHEMBL25234167 | 0.81 | CYP1A2 (0.49) | LMNACYP1A2CYP3A4MAOAHSP90AA1 | |
| SCHEMBL8091063 | 0.81 | CYP2C9 (0.50) | LMNACYP1A2CYP3A4MAOACYP2C9 | |
| SCHEMBL12461092 | 0.81 | CYP2C9 (0.50) | LMNACYP1A2CYP3A4MAOACYP2C9 | |
| SCHEMBL18198247 | 0.81 | CYP2C9 (0.50) | LMNACYP1A2CYP3A4MAOACYP2C9 | |
| SCHEMBL829286 | 0.81 | CYP2C9 (0.50) | LMNACYP1A2CYP3A4MAOAKDM4E | |
| SCHEMBL19779421 | 0.81 | CA12 (0.53) | LMNACYP1A2CYP3A4MAOAKDM4E | |
| SCHEMBL8884857 | 0.81 | CYP2C9 (0.50) | LMNACYP1A2CYP3A4MAOACYP2C9 | |
| SCHEMBL465881 | 0.80 | LMNA (0.61) | LMNACYP1A2CYP3A4MAOACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695253-A1 | IMIDAZO BICYCLIC DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2025-02-27 | — | — | US | disclosed |
| EP-4460505-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | Nodthera Limited (GB) | 2024-11-13 | — | — | EP | disclosed |
| CN-118922421-A | Bicyclic phthalazin-1 (2H) -one derivatives and related uses | 诺瑟拉有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024213664-A1 | IMIDAZO BICYCLIC DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-117916237-A | Amino aryl integrin agonist compounds | 德克萨斯心脏研究所 | 2024-04-19 | — | — | CN | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | ALLEN CHRISTOPHER (US) | 2004-10-14 | — | — | US | disclosed |
| EP-1399160-A4 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO INC (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2003-06-26 | — | — | US | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| US-5691323-A | BENZIMIDAZOL-2-ONES | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| US-3957785-A | ADRENOLYTICS, NONTOXIC, HYPOTENSIVE AGENTS, ANALGESICS | SOCIETA' FARMACEUTICI ITALIA S.P.A. (IT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | IL1B, NLRP3, IL1A | LMNA 2123/4885CYP1A2 1715/4885CYP3A4 3067/4885 |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | LMNA 121/4885CYP1A2 3934/4885CYP3A4 4853/4885 |
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | HTR1B, HTR2B, HTR1A | LMNA 1404/4885CYP1A2 866/4885CYP3A4 3194/4885 |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | ITGB3, ITGA2, ITGAV | LMNA 2476/4885CYP1A2 2939/4885CYP3A4 2612/4885 |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | GRIN1, GRIN2B, GRIN2A | LMNA 4716/4885CYP1A2 3284/4885CYP3A4 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.